N. G. Bendeliani

N. G. Bendeliani

Auto-generated profile, based on publicly available information

N. G. Bendeliani

Institute for Coronary and Vascular Surgery of A.N. Bakulev National Medical Research Center of Cardiovascular Surgery

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2019 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Open access
PDF file
SGS. R. Gilyarevsky
S. R. Gilyarevsky
MGM. V. Golshmid
M. V. Golshmid
ИКИ. М. Кузьмина
И. М. Кузьмина
NBN. G. Bendeliani
N. G. Bendeliani
The article reports the modern tactics of treating patients with chronic heart failure and concomitant anemia. The results of the most important randomized clinical trials that are the basis for developing approaches to the treatment of anemia in such cases are discussed. Attention is also paid to unresolved problems in the treatment of anemia in patients with heart failure. The data on the intravenous administration of iron preparations as the most effective approach to the treatment of anemia in patients with heart failure in the presence of iron defciency are given. The main provisions of modern clinical guidelines on the management of patients with heart failure and anemia are considered.

29 May 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
SGS. R. Gilyarevskij
S. R. Gilyarevskij
NBN. G. Bendeliani
N. G. Bendeliani
MGM. V. Golshmid
M. V. Golshmid
IKI. M. Kuz’mIna
I. M. Kuz’mIna
IAI. G. Andreeva
I. G. Andreeva
ПРИМЕНЕНИЕ КОМБИНИРОВАННЫХ ПРЕПАРАТОВ С ПОСТОЯННЫМИ ДОЗАМИ АНТИГИПЕРТЕНЗИВНЫХ СРЕДСТВ КАК НАЧАЛЬНАЯ ТАКТИКА ЛЕЧЕНИЯ ПРИ ПОВЫШЕННОМ УРОВНЕ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ: ДОКАЗАННЫЕ ФАКТЫ И МНЕНИЕ ЭКСПЕРТОВ

8 September 2022 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
SGS. R. Gilyarevsky
S. R. Gilyarevsky
MGM. V. Golshmid
M. V. Golshmid
NBN. G. Bendeliani
N. G. Bendeliani
Aim. To evaluate the effect of taking a single pill combination of amlodipine, lisinopril and rosuvastatin on blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in hypertensive patients with or without severe hypercholesterolemia.Material and methods. Articles published in Russian were selected for analysis. Six articles that met the criteria for inclusion in a systematic review were found by searching the eLibrary database for the keyword "equamer". The results of 5 observational clinical studies were presented in these articles. The effectiveness of the fixed combination of amlodipine, lisinopril and rosuvastatin was assessed mainly by changes in the level of systolic and diastolic blood pressure, the concentration of LDL cholesterol. In addition, the effects of fixed-dose amlodipine, lisinopril, and rosuvastatin on central aortic pressure and its increment index, as well as carotid-femoral pulse wave velocity, were studied in part of the studies. The effect of the fixed combination of amlodipine, lisinopril and rosuvastatin on blood pressure and LDL-C concentration, as well as on these additional indicators, in patients who had a coronavirus infection with severe lung damage was studied in one study.Results. Evidence from a systematic review demonstrates the efficacy of single pill combination amlodipine, lisinopril and rosuvastatin in reducing blood pressure and LDL-C in a wide range of patients with different baseline risk of developing cardiovascular complications and different baseline levels of blood pressure and LDL-C.Conclusion. The data obtained confirm the feasibility of more frequent prescription of the single pill combination of amlodipine, lisinopril and rosuvastatin in clinical practice for the treatment of hypertensive patients with high or moderate risk of developing cardiovascular diseases, including patients with concomitant hypercholesterolemia.

7 September 2020 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
SGS. R. Gilyarevsky
S. R. Gilyarevsky
NBN. G. Bendeliani
N. G. Bendeliani
MGM. V. Golshmid
M. V. Golshmid
GZG. Yu. Zaharova
G. Yu. Zaharova
IKI. M. Kuzmina
I. M. Kuzmina
ISIrina Ivanovna Sinitcina
Irina Ivanovna Sinitcina
The article discusses results of secondary analysis of the data obtained in the SPRINT study and published in recent years. Unresolved issues in the tactics of managing patients with arterial hypertension are discussed. One of such issues is choosing an optimum level of blood pressure (BP) for a subgroup of patients with certain characteristics, including elderly and senile patients, patients with chronic kidney disease, and patients with arterial hypertension who continue smoking. The article discusses calculation of a threshold of risk for complications of cardiovascular diseases, at which a maximum advantage of intensified regimens of antihypertensive therapy could be achieved. In addition, the article addresses approaches to selection of antihypertensive drugs in the current conditions. The authors discussed the role of candesartan in the treatment of arterial hypertension, a sartan most studied in a broad range of patients. The issue of a rapid increase in BP without a damage to target organs is addressed; evidence for the role of captopril in such clinical situation is provided.

18 October 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SGS. R. Gilyarevskiy
S. R. Gilyarevskiy
NBN. G. Bendeliani
N. G. Bendeliani
MGM. V. Golshmid
M. V. Golshmid
ИКИ. М. Кузьмина
И. М. Кузьмина
The article presents updated information on the frequency of use of non-recommended low dosing of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). It gives substantiation of the urgency of the issue of providing the maximum efficiency of the use of anticoagulants in clinical practice, taking into account the high prevalence of atrial fibrillation and the pharmacological characteristics of the most commonly used drugs. The effects of such an unreasonable reduction in anticoagulant doses in elderly and senile patients are discussed. The results of recent observational studies that assessed the relationship between the use of direct oral anticoagulants and the risk of adverse clinical outcomes are presented. The data on the relationship between the use of unreasonably low dosing of anticoagulants in patients with atrial fibrillation, which were recently obtained during the implementation of the GARFIELD-AF registry, are discussed. The data on a rather high variability of concentrations of direct oral anticoagulants are presented. The frequency of using apixaban in an unreasonably reduced dose, as well as the effects of using non-recommended doses of apixaban hold a specific place in the article. The unreasonableness of attempts to further reduce the risk of bleeding due to unreasonable reduction of apixaban dosing is emphasized, taking into account the stable data on the high safety of recommended dosing of apixaban, as well as the possible decrease in the effect if the dose reduction is not recommended. The data on the criteria for dose reduction, which are adopted in different countries, are presented. The proposed terms to designate different doses of direct oral anticoagulants, depending on their study in the course of large, randomized trials are discussed.

28 January 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SGS. R. Gilyarevsky
S. R. Gilyarevsky
MGM. V. Golshmid
M. V. Golshmid
NBN. G. Bendeliani
N. G. Bendeliani
ИКИ. М. Кузьмина
И. М. Кузьмина
GZG. Y. Zaharova
G. Y. Zaharova
CГC. Р. Гиляревский
C. Р. Гиляревский
The article discusses the vascular age concept and modern approaches to assessing vascular age. It describes modern methods for measuring arterial stiffness (applanation tonometry or ultrasonic Doppler examination) as the most frequently used index of vascular age. The authors discuss the role of antihypertensive therapy and statins in preventing early vascular aging, and the relationship between the role of achieving lower blood pressure levels and the choice of certain antihypertensive agents to reduce arterial stiffness and ensure optimal vascular age. Increased arterial stiffness has been reported to be a marker of risk for developing severe complications of cardiovascular diseases, in particular, a meta-analysis showed that after taking into account the known risk factors for developing cardiovascular complications, higher carotid stiffness was associated with an increased risk of stroke. It is stated that in addition to biological age, vascular age may increase due to the cumulative effect of such risk factors as high blood pressure, impaired glucose homeostasis, obesity and hypercholesterolemia. Modern approaches to the preservation and maintenance of vascular age are discussed. The key role of achieving lower blood pressure levels is considered. It is emphasized that the role of combination drugs in preventing complications of cardiovascular diseases is strengthened, and approaches to choosing the optimal components of such combination drugs are also considered. The relationship between increased arterial stiffness and the development of cognitive disorders is discussed. The article describes the role of statins and effectiveness of the concomitant use of statins and combination antihypertensive therapy in reducing the pulse wave velocity.